We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Horiba Medical (Kyoto, Japan) presented its high-end hematology solutions alongside different configurations of laboratory organization as well as its comprehensive range of hemostasis and clinical chemistry instruments at MEDLAB Middle East 2021.

On display at the event were the Yumizen H2500, Yumizen SPS and Yumizen P8000 - the new generation of Horiba automated hematology analyzers that answers customers’ expectations of solid and reliable diagnostic technology as well as rapid and consistent results. More...
Some of their features include a real throughput of 120 samples per hour for CBC-DIFF, NRBC included, sampling volume of 110μl (CBC, DIFF, BF) and 75μL (Slide), only six reagents, automatic 360° rotative sample mixing for perfect homogeneity, two PLT technologies - Impedance & Optical extinction – and three WBC counts in CBC and differential modes. All the instruments are compatible with the HELO Solution (HORIBA Evolutive Laboratory Organization).

Horiba also showcased its Yumizen H500 and H550 analyzers that have been designed to deliver a rapid and comprehensive hematology report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, urgent manual mode; and for running samples through multi analysis modes and sampling. Based on color codes, minimum operation and quality flagging messages, the ergonomics of the new Yumizen H500 and H550 are perfectly dedicated to users of small size laboratories such as emergency rooms or physician office labs. With its menu of extensive parameters and enhanced clinical performances the new Yumizen H500 and H550 analyzers are capable of meeting the demands of a variety of clinical lab environments and clinical settings: routine hematology, satellites labs, oncology care, blood banks.

In addition, Horiba highlighted the Microsemi LC-667G hematology analyzer featuring the exclusive concept of simultaneous blood analysis + CRP measurement, along with data management. It is the first hematology analyzer to offer malaria screening flag combined with CBC count. The Malaria screening flag with high sensitivity alerts the physician about suspicion of malaria infection and is available in CBC or CBC+CRP routine use without any specific reagent or dedicated mode. The added value is part of a complete solution of using the MicrosEmi CRP as an infectious differentiator.

Related Links:
Horiba Medical


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Serological Pipet Controller
PIPETBOY GENIUS
New
Mini Vortex Mixer
Vornado
New
PBC Assay
Primary Biliary Cholangitis Assays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.